March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Impact of Lucentis on Psychological Morbidity in Patients with Macular Edema and Neovascularization Secondary to Retinal Vein Occlusion
Author Affiliations & Notes
  • Lawrence J. Singerman
    Retina Associates of Cleveland, Cleveland, Ohio
  • Dianne R. Himmelman
    Retina Associates of Cleveland, Cleveland, Ohio
  • Burton Singerman
    Intercare Behavioral Health Systems, Pittsburgh, Pennsylvania
  • Akshay Thomas
    Case Western Reserve University School of Medicine, Cleveland, Ohio
  • Lucy Newman
    International Baccalaureate Program, Pittsburgh, Pennsylvania
  • Joseph M. Coney
    Retina Associates of Cleveland, Cleveland, Ohio
  • Jerome P. Schartman
    Retina Associates of Cleveland, Cleveland, Ohio
  • Michael A. Novak
    Retina Associates of Cleveland, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  Lawrence J. Singerman, Genentech (F); Dianne R. Himmelman, Genentech (F); Burton Singerman, Genentech (F); Akshay Thomas, None; Lucy Newman, None; Joseph M. Coney, Genentech (F); Jerome P. Schartman, Genentech (F); Michael A. Novak, Genentech (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5466. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lawrence J. Singerman, Dianne R. Himmelman, Burton Singerman, Akshay Thomas, Lucy Newman, Joseph M. Coney, Jerome P. Schartman, Michael A. Novak; Impact of Lucentis on Psychological Morbidity in Patients with Macular Edema and Neovascularization Secondary to Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5466.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The purpose of this prospective, single-center, non-randomized study was to assess the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or branch retinal vein occlusion.

Methods: : Thirty consecutive patients with retinal vein occlusion (RVO) and macular edema were given intravitreal ranibizumab at each of 6 consecutive visits at 4-week intervals. Ophthalmology status was assessed with examination, refraction, OCT, and FA. Psychological status was assessed with the Visual Function Questionnaire (VFQ25), which was subdivided into the 9-question general mental health questions (VFQ9, mental health); the Patient Health Questionnaire (PHQ9); and the General Health Questionnaire (GHQ12). A comparison group of 15 patients with inactive RVO not treated with any anti-VEGF agent was assessed with the same questionnaires in the same 24-week period.

Results: : The change in the PHQ-9 score was not statistically different between the treatment and comparison groups. The mean change in GHQ12 score was a reduction of 2.6 (SD 4.25) for the treatment group and a gain of 0.33 (SD 4.13) for the comparison group. The mean change in score was statistically significant between the groups (p =.034). The mean change in the VFQ-9 score for the treatment group was +7.8; for the comparison group, -4.6. The mean change in VFQ-9 score was statistically significant between the groups (p <.0001). Patients receiving intravitreal Lucentis injections gained an average of 14.3 letters (median 15, SD 16.5) and had a mean reduction in central retinal thickness of 283.6 microns (median 261, SD 324) at the end of the 24-week study.

Conclusions: : In subjects with RVO, Lucentis treatment was associated with significant improvement in psychological status by both the well-validated GHQ12 and the VFQ9 mental health, both of which assess probability of mental health morbidity. This occurred even though most subjects had near-normal vision in the uninvolved eye and thus did not have much psychological distress at the start of the study. Lucentis-treated subjects had significant improvement in vision in the involved eye, with reduction in macular edema.

Clinical Trial: : http://www.clinicaltrials.gov NCT01011374

Keywords: vascular occlusion/vascular occlusive disease • clinical (human) or epidemiologic studies: outcomes/complications • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×